Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11760755 Hepatitis B antiviral agents

Patent 11760755 was granted and assigned to Enanta Pharmaceuticals on September, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

Enanta Pharmaceuticals

Date Filed

June 4, 2020

Date of Patent

September 19, 2023

Patent Applicant

Enanta Pharmaceuticals

Patent Application Number

16892373

Patent Citations

‌

US Patent 7615569 Inhibitors of ion channels

‌

US Patent 7232825 Phenylaminopyrimidine derivatives and methods of use

‌

US Patent 7312214 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors

‌

US Patent 7411003 Inhibition of Hepatitis B virus by cyclohexenone compounds from

‌

US Patent 8420823 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient

‌

US Patent 9447086 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

‌

US Patent 9498479 Dihydropyrimidine compounds and their application in pharmaceuticals

‌

US Patent 9573941 Processes for preparing dihydropyrimidine derivatives and intermediates thereof

‌

US Patent 9617252 Processes for preparing dihydropyrimidine derivatives and intermediates thereof

‌

US Patent 9938301 Dihydropyrimido fused ring derivative as HBV inhibitor

•••

Patent Inventor Names

Jorden Kass

Jiajun Zhang

Xiaowen Peng

Byung-Chul Suh

Yao-Ling Qiu

Xuri Gao

Hui Cao

Wei Li

Yat Sun Or

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11760755

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11760755 Hepatitis B antiviral agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.